source
- ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loomAs the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…